Biological variations in plasma VEGF and VEGFR-1 may compromise their biomarker value in colorectal cancer

References

• Risau W. Mechanisms of angiogenesis. Nature 1997;386:671–4.
   PubMed Web of Science ®Google Scholar
• Carmeliet P, Jain RK. Angiogenesis in cancer and other diseases. Nature 2000;407:249–57.
   PubMed Web of Science ®Google Scholar
• Folkman J. Tumor angiogenesis and tissue factor. Nat Med 1996;2:167–8.
   PubMed Web of Science ®Google Scholar
• Asahara T, Masuda H, Takahashi T, Kalka C, Pastore C, Silver M, Kearne M, Magner M, Isner JM. Bone marrow origin of endothelial progenitor cells responsible for postnatal vasculogenesis in physiological and pathological neovascularization. Circ Res 1999;85:221–8.
   PubMed Web of Science ®Google Scholar
• Hillen F, Griffioen AW. Tumour vascularization: sprouting angiogenesis and beyond. Cancer Metastasis Rev 2007;26: 489–502.
   PubMed Web of Science ®Google Scholar
• Kliche S, Waltenberger J. VEGF receptor signaling and endothelial function. IUBMB Life 2001;52:61–6.
   PubMed Web of Science ®Google Scholar
• Ortega N, Hutchings H, Plouet J. Signal relays in the VEGF System. Front Biosci 1999;4:D141–52.
   Google Scholar
• Barleon B, Reusch P, Totzke F, Herzog C, Keck C, Martiny-Baron G, Marme D. Soluble VEGFR-1 secreted by endothelial cells and monocytes is present in human serum and plasma from healthy donors. Angiogenesis 2001;4: 143–54.
   PubMedGoogle Scholar
• Goldman CK, Kendall RL, Cabrera G, Soroceanu L, Heike Y, Gillespie GY, Siegal GP, Mao X, Bett AJ, Huckle WR, Thomas KA, Curiel DT. Paracrine expression of a native soluble vascular endothelial growth factor receptor inhibits tumor growth, metastasis, and mortality rate. Proc Natl Acad Sci USA 1998;95:8795–800.
   PubMed Web of Science ®Google Scholar
• Anthony T, Fleming JB, Bieligk SC, Sarosi GA, Kim LT, Gregorcyk SG, Simmang CL, Turnage RH. Postoperative colorectal cancer surveillance. J Am Coll Surg 2000;190: 737–49.
   PubMed Web of Science ®Google Scholar
• Graziano F, Cascinu S. Prognostic molecular markers for planning adjuvant chemotherapy trials in dukes’ B colorectal cancer patients: how much evidence is enough? Ann Oncol 2003;14:1026–38.
   PubMed Web of Science ®Google Scholar
• Takahashi Y, Kitadai Y, Bucana CD, Cleary KR, Ellis LM. Expression of vascular endothelial growth factor and its receptor, KDR, correlates with vascularity, metastasis, and proliferation of human colon cancer. Cancer Res 1995;55: 3964–8.
   PubMed Web of Science ®Google Scholar
• Papamichael D. Prognostic role of angiogenesis in colorectal cancer. Anticancer Res 2001;21:4349–53.
   PubMed Web of Science ®Google Scholar
• Roumen RM, Slooter GD, Croiset van Uchelen FA, Huib LV. Preoperative serum vascular endothelial growth factor is not a marker for subsequent recurrence during long-term follow-up of colorectal cancer patients. Dis Colon Rectum 2005;48:1070–5.
   PubMed Web of Science ®Google Scholar
• Karayiannakis AJ, Syrigos KN, Zbar A, Baibas N, Polychronidis A, Simopoulos C, Karatzas G. Clinical significance of preoperative serum vascular endothelial growth factor levels in patients with colorectal cancer and the effect of tumor surgery. Surgery 2002;131:548–55.
   PubMed Web of Science ®Google Scholar
• Werther K, Christensen IJ, Nielsen HJ. Prognostic impact of matched preoperative plasma and serum VEGF in patients with primary colorectal carcinoma. Br J Cancer 2002;86: 417–23.
   PubMed Web of Science ®Google Scholar
• Gonzalez FJ, Quesada AR, Sevilla I, Baca JJ, Medina MA, Amores J, Diaz JM, Rius-Diaz F, Marques E, Alba E. Prognostic value of serum angiogenic activity in colorectal cancer patients. J Cell Mol Med 2007;11:120–8.
   PubMed Web of Science ®Google Scholar
• Nakayama Y, Sako T, Shibao K, Okazaki K, Rempo N, Onitsuka K, Minagawa N, Akahane K, Nagashima N, Nagata N, Itoh H. Prognostic value of plasma vascular endothelial growth factor in patients with colorectal cancer. Anticancer Res 2002;22:2437–42.
   PubMed Web of Science ®Google Scholar
• Tsai WS, Changchien CR, Yeh CY, Chen JS, Tang R, Chiang JM, Hsieh PS, Fan CW, Wang JY. Preoperative plasma vascular endothelial growth factor but not nitrite is a useful complementary tumor marker in patients with colorectal cancer. Dis Colon Rectum 2006;49:883–94.
   PubMed Web of Science ®Google Scholar
• Svendsen MN, Werther K, Nielsen HJ, Kristjansen PE. VEGF and tumour angiogenesis. impact of surgery, wound healing, inflammation and blood transfusion. Scand J Gastroenterol 2002;37:373–9.
   PubMed Web of Science ®Google Scholar
• Werther K, Christensen IJ, Nielsen HJ. Determination of vascular endothelial growth factor (VEGF) in circulating blood: significance of VEGF in various leucocytes and platelets. Scand J Clin Lab Invest 2002;62:343–50.
   PubMed Web of Science ®Google Scholar
• Svendsen MN, Werther K, Christensen IJ, Basse L, Nielsen HJ. Influence of open versus laparoscopically assisted colectomy on soluble vascular endothelial growth factor (SVEGF) and its soluble receptor 1 (SVEGFR1). Inflamm Res 2005;54: 458–63.
   PubMed Web of Science ®Google Scholar
• Selheim F, Holmsen H, Vassbotn FS. Identification of functional VEGF receptors on human platelets. FEBS Lett 2002;512:107–10.
   PubMed Web of Science ®Google Scholar
• Caine GJ, Lip GY, Blann AD. Platelet-derived VEGF, Flt-1, Angiopoietin-1 and P-Selectin in breast and prostate cancer: further evidence for a role of platelets in tumour angiogenesis. Ann Med 2004;36:273–7.
   PubMed Web of Science ®Google Scholar
• de PA, Prevete N, Fiorentino I, Rossi FW, Staibano S, Montuori N, Ragno P, Longobardi A, Liccardo B, Genovese A, Ribatti D, Walls AF, Marone G. Expression and functions of the vascular endothelial growth factors and their receptors in human basophils. J Immunol 2006;177:7322–31.
   PubMed Web of Science ®Google Scholar
• Ancelin M, Chollet-Martin S, Herve MA, Legrand C, El BJ, Perrot-Applanat M. Vascular endothelial growth factor VEGF189 induces human neutrophil chemotaxis in extravascular tissue via an autocrine amplification mechanism. Lab Invest 2004;84:502–12.
   PubMed Web of Science ®Google Scholar
• Feistritzer C, Kaneider NC, Sturn DH, Mosheimer BA, Kahler CM, Wiedermann CJ. Expression and function of the vascular endothelial growth factor receptor FLT-1 in human eosinophils. Am J Respir Cell Mol Biol 2004;30:729–35.
   PubMed Web of Science ®Google Scholar
• Chin KF, Greenman J, Reusch P, Gardiner E, Marme D, Monson J. Changes in serum soluble VEGFR-1 and Tie-2 receptors in colorectal cancer patients following surgical resections. Anticancer Res 2004;24:2353–7.
   PubMed Web of Science ®Google Scholar
• Kumar H, Heer K, Greenman J, Kerin MJ, Monson JR. Soluble FLT-1 is detectable in the sera of colorectal and breast cancer patients. Anticancer Res 2002;22:1877–80.
   PubMed Web of Science ®Google Scholar
• Chin KF, Greenman J, Reusch P, Gardiner E, Marme D, Monson JR. Vascular endothelial growth factor and soluble tie-2 receptor in colorectal cancer: associations with disease recurrence. Eur J Surg Oncol 2003;29:497–505.
   PubMedGoogle Scholar
• Nielsen HJ, Brunner N, Frederiksen C, Lomholt AF, King D, Jorgensen LN, Olsen J, Rahr HB, Thygesen K, Hoyer U, Laurberg S, Christensen IJ. Plasma tissue inhibitor of metalloproteinases-1 (TIMP-1): a novel biological marker in the detection of primary colorectal cancer. Protocol outlines of the Danish-Australian Endoscopy Study Group on Colorectal Cancer Detection. Scand J Gastroenterol 2008;43:242–8.
   PubMed Web of Science ®Google Scholar
• Kirkwood TBL. Geometric means and measures of dispersion. Biometrics 1979;35:908–9.
   Google Scholar
• Berrahmoune H, Lamont JV, Herbeth B, Fitzgerald PS, Visvikis-Siest S. Biological determinants of and reference values for plasma interleukin-8, monocyte chemoattractant protein-1, epidermal growth factor, and vascular endothelial growth factor: results from the STANISLAS cohort. Clin Chem 2006;52:504–10.
   PubMed Web of Science ®Google Scholar
• Brostjan C, Bayer A, Zommer A, Gornikiewicz A, Roka S, Benko T, Yaghubian R, Jakesz R, Steger G, Gnant M, Friedl J, Stift A. Monitoring of circulating angiogenic factors in dendritic cell-based cancer immunotherapy. Cancer 2003;98: 2291–301.
   PubMed Web of Science ®Google Scholar
• Hetland ML, Christensen IJ, Lottenburger T, Johansen JS, Svendsen MN, Horslev-Petersen K, Nielsen L, Jorgen NH. Circulating VEGF as a biological marker in patients with rheumatoid arthritis? Preanalytical and biological variability in healthy persons and in patients. Dis Markers 2008;24:1–10.
   PubMed Web of Science ®Google Scholar
• Hanrahan V, Currie MJ, Gunningham SP, Morrin HR, Scott PA, Robinson BA, Fox SB. The angiogenic switch for vascular endothelial growth factor (VEGF)-A, VEGF-B, VEGF-C, and VEGF-D in the adenoma-carcinoma sequence during colorectal cancer progression. J Pathol. 2003;200:183–94.
   PubMed Web of Science ®Google Scholar
• Svendsen MN, Lykke J, Werther K, Christensen IJ, Nielsen HJ. Concentrations of VEGF and VEGFR1 in paired tumor arteries and veins in patients with rectal cancer. Oncol Res 2004;14:611–5.
   PubMed Web of Science ®Google Scholar
• Henic E, Borgfeldt C, Christensen IJ, Casslen B, Hoyer-Hansen G. Cleaved forms of the urokinase plasminogen activator receptor in plasma have diagnostic potential and predict postoperative survival in patients with ovarian cancer. Clin Cancer Res 2008;14:5785–93.
   PubMed Web of Science ®Google Scholar